No Data
Baipu Science (301080.SZ): The company is building an AI technology application platform, which will be applied to the transformation process of proteins.
On August 15th, Gelonghui reported that Baipu Saishi (301080.SZ) on the investor interaction platform stated that AI technology, with its powerful data processing and analysis capabilities, is gradually changing the research and development process of the innovative drug industry. Currently, the company is building an AI technology application platform and applying the technology to the protein modification process. Through collaborative AI calculation and simulation of "dry experiments" and high-throughput "wet experiments," AI technology is combined with computationally based virtual screening methods, continuously closed, and iterated to ultimately obtain specific proteins. Taking universal nucleases as an example, it is essentially a protein, in order to meet.
Is AcrobiosystemsLtd (SZSE:301080) Using Too Much Debt?
ACROBiosystems Launches GMP Brand Resilient Supply at ISSCR to Accelerate Cell and Gene Therapy Development
Baipusi (301080.SZ) plans to distribute 9 yuan per 10 shares, with ex-rights and ex-dividends on July 5.
Baipu Saisi (301080.SZ) announced that the company plans to distribute annual equity dividends in 2023, with a distribution of 1.0 yuan (tax included) for every 10 shares to all shareholders.
Express News | Syntekabio Signs Memorandum of Understanding With Bioseedin/Acrobiosystems
Acrobiosystems Co.,Ltd.'s (SZSE:301080) Most Bullish Insider, CEO Yiding Chen Must Be Pleased With the Recent 10% Gain
No Data
